DrugPatentWatch Database Preview

Details for Patent: 8,047,202

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,047,202 protect, and when does it expire?

Patent 8,047,202 protects ONZETRA XSAIL and is included in one NDA.

This patent has five patent family members in three countries.

Summary for Patent: 8,047,202

Title:	Nasal devices
Abstract:	A nasal delivery device and a method of delivering substance to a nasal airway of a subject, can be used for mass treatment, especially mass vaccination. The delivery device can include an interface unit, as a replaceable unit, having at least one nosepiece unit for fitting to a respective nostril of a subject, a nozzle from which substance is in use delivered, and at least one delivery unit having a substance supply unit for delivering substance to the nozzle of the at least one nosepiece unit. The delivery device can also include an actuation unit for actuating the at least one delivery unit of the interface unit.
Inventor(s):	Djupesland; Per Gisle (Oslo, NO)
Assignee:	OptiNose AS (Oslo, NO)
Application Number:	12/339,716
Patent Claim Types: see list of patent claims	Delivery; Device;

Drugs Protected by US Patent 8,047,202

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Currax	ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099-001	Jan 27, 2016		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 8,047,202

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0215270.0	Jul 2, 2002

International Family Members for US Patent 8,047,202

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003251088
United Kingdom	0215270
United Kingdom	0315499
United Kingdom	2390813
World Intellectual Property Organization (WIPO)	2004004814